Luteolin ameliorates neurological deficits and dopaminergic neuronal damage in MPTP-induced Parkinson’s disease mice via regulating the AKT/BNIP3 mitophagy signaling axis

Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Luteolin, a natural dietary flavonoid monomer, exhibits neuroprotective potential; however, its molecular targets and regulatory mechanisms in PD require further exploration. Methods Network pharmacology was employed to predict potential targets of Luteolin against PD. Subsequently, a subacute MPTP-induced PD mouse model was established to evaluate the preventive and therapeutic effects of Luteolin (20, 40, and 100 mg/kg), with levodopa/benserazide serving as a symptomatic pharmacological reference. Motor performance, serum biosafety indicators (ALT, AST, BUN, Cr, CK), pro-inflammatory cytokines, oxidative stress markers, TH-positive neuronal survival, and AKT/BNIP3/LC3 pathway proteins were systematically evaluated. Results Network analysis prioritized AKT1 as a top hub target linking Luteolin to PD pathogenesis. In vivo experiments showed that MPTP intoxication led to severe motor deficits, depletion of SNpc TH-positive neurons (preserving only 43.1% compared with the Normal group, 7.50 ± 1.87 vs. 17.40 ± 2.65 cells/field, P < 0.01), elevated oxidative stress (increased ROS and MDA, decreased SOD), and reduced expression of TH, p-AKT/AKT (decreased by 67.3%), BNIP3 (decreased by 66.7%), and LC3-II/I (all P < 0.01). Luteolin treatment, particularly at medium (40 mg/kg) and high (100 mg/kg) doses, significantly attenuated oxidative stress and central inflammation (TNF-α, IL-1β, IL-6), preserved TH-positive neurons (high-dose preserving 93.1% of control levels, 16.20 ± 2.39 cells/field), and upregulated p-AKT/AKT and BNIP3 protein levels, while serum biochemical parameters of hepatic and renal functions remained within physiological baseline ranges with no significant group differences ( P > 0.05). Conclusion Luteolin confers robust neuroprotection against MPTP neurotoxicity, which is closely associated with anti-inflammatory activity, attenuation of oxidative stress, and positive modulation of AKT/BNIP3 mitophagy-related signaling proteins.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.3389/fphar.2026.1993520
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Luteolin ameliorates neurological deficits and dopaminergic neuronal damage in MPTP-induced Parkinson’s disease mice via regulating the AKT/BNIP3 mitophagy signaling axis

Fuqiang Xi, Jinqi Hao, Ying Wang, Jing Ma et al.
Frontiers in Pharmacology
Parkinson's Disease Mechanisms and Treatments
article

Luteolin ameliorates neurological deficits and dopaminergic neuronal damage in MPTP-induced Parkinson’s disease mice via regulating the AKT/BNIP3 mitophagy signaling axis

Fuqiang Xi, Jinqi Hao, Ying Wang, Jing Ma, Yunchang Gu
article en

Abstract

Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Luteolin, a natural dietary flavonoid monomer, exhibits neuroprotective potential; however, its molecular targets and regulatory mechanisms in PD require further exploration. Methods Network pharmacology was employed to predict potential targets of Luteolin against PD. Subsequently, a subacute MPTP-induced PD mouse model was established to evaluate the preventive and therapeutic effects of Luteolin (20, 40, and 100 mg/kg), with levodopa/benserazide serving as a symptomatic pharmacological reference. Motor performance, serum biosafety indicators (ALT, AST, BUN, Cr, CK), pro-inflammatory cytokines, oxidative stress markers, TH-positive neuronal survival, and AKT/BNIP3/LC3 pathway proteins were systematically evaluated. Results Network analysis prioritized AKT1 as a top hub target linking Luteolin to PD pathogenesis. In vivo experiments showed that MPTP intoxication led to severe motor deficits, depletion of SNpc TH-positive neurons (preserving only 43.1% compared with the Normal group, 7.50 ± 1.87 vs. 17.40 ± 2.65 cells/field, P < 0.01), elevated oxidative stress (increased ROS and MDA, decreased SOD), and reduced expression of TH, p-AKT/AKT (decreased by 67.3%), BNIP3 (decreased by 66.7%), and LC3-II/I (all P < 0.01). Luteolin treatment, particularly at medium (40 mg/kg) and high (100 mg/kg) doses, significantly attenuated oxidative stress and central inflammation (TNF-α, IL-1β, IL-6), preserved TH-positive neurons (high-dose preserving 93.1% of control levels, 16.20 ± 2.39 cells/field), and upregulated p-AKT/AKT and BNIP3 protein levels, while serum biochemical parameters of hepatic and renal functions remained within physiological baseline ranges with no significant group differences ( P > 0.05). Conclusion Luteolin confers robust neuroprotection against MPTP neurotoxicity, which is closely associated with anti-inflammatory activity, attenuation of oxidative stress, and positive modulation of AKT/BNIP3 mitophagy-related signaling proteins.

Frontiers in PharmacologyVol. 17
Baotou Medical College (CN)
Natural Science Foundation of Inner Mongolia
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon